Trista Morrison

In a deal worth up to $100 million, Micromet Inc. licensed the preclinical anti-angiogenesis monoclonal antibody D93 to privately held Tracon Pharmaceuticals Inc. (BioWorld Today)

Tracon Licenses D93 Antibody From Micromet

March 19, 2007

By Trista Morrison

In a deal worth up to $100 million, Micromet Inc. licensed the preclinical anti-angiogenesis monoclonal antibody D93 to privately held Tracon Pharmaceuticals Inc. (BioWorld Today)

Pfizer, Biogen Idec Launch Incubators To Build Pipelines

March 19, 2007

By Trista Morrison

Articles by Trista Morrison

Cannasat and IntelGenx Expand Cannabinoid-Based Collaboration

Cannasat and IntelGenx Expand Cannabinoid-Based Collaboration

Cleveland BioLabs Raises $30M, Pursues DOD Contract

Intarcia Is Re-Born With $50M Series BB Financing

Intarcia Is Re-Born With $50M Series BB Financing

Cleveland BioLabs Raises $30M, Pursues DOD Contract

Pfizer, Biogen Idec Launch Incubators To Build Pipelines

Tracon Licenses D93 Antibody From Micromet

Tracon Licenses D93 Antibody From Micromet

Pfizer, Biogen Idec Launch Incubators To Build Pipelines

Today's news in brief

Detecting the invisible: minimal residual disease at AACR 2026

News in brief

Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists

Pharma industry faces long haul to get return on investment from AI